1 / 7

CrAg lateral flow assay - method

CrAg lateral flow assay - method. Serotype sensitivity of LFA for CrAg. EIA vs . LFA with patient samples. Paired samples from 62 patients with culture-proven cryptococcosis Samples assayed by quantitative EIA and titers by LFA. Method Comparison CDC Thai Study. CDC Retrospective Study

lenore-king
Télécharger la présentation

CrAg lateral flow assay - method

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CrAg lateral flow assay - method

  2. Serotype sensitivity of LFA for CrAg

  3. EIA vs. LFA with patient samples • Paired samples from 62 patients with culture-proven cryptococcosis • Samples assayed by quantitative EIA and titers by LFA

  4. Method Comparison CDC Thai Study • CDC Retrospective Study • Sera, HIV+, acute respiratory illness, Thailand, results @ 15 min Lateral flow vs EIA Lateral flow vs culture

  5. IMMY CrAg LFA vs. IMMY CrAg LA • Serum and CSF from archived samples • Evaluated by lateral flow and latex agglutination Serum Specimens CSF Specimens

  6. Diagnostics for the developing world: critical characteristics • The right diagnostic target • CrAg is a proven target • The LFA has high sensitivity for all serotypes • The right specimen type • CE Mark approved for serum and CSF (pending US FDA approval) • Phase II will target urine, plasma and whole fingerprick blood • The right assay platform • LFA meets all ASSURED criteria – extremely inexpensive, user-friendly, rapid, equipment-free, etc. • Next generation platform – Quantitative? 2 1 7.8 3.9 500 250 125 15.6 62.5 31.3 1000 CrAg (ng/ml)

  7. Acknowledgments IMMYSt. Georges University of London Brandon Neary Thomas Harrison Joy Pelfrey Joseph Jarvis Brian Doherty Desmond Tutu Centre/GF Jooste Hospital University of Nevada, RenoCape Town, South Africa Ann Percival Graeme Mientjes Marcellene Gates-Hollingsworth G. Ntombomzi Williams Nicky Longley NIH/NIAID: AI014209

More Related